Milsaperidone (VHX-896) vs Quetiapine (Seroquel XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Quetiapine (Seroquel XR)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Weak signal

NCT00640601 · Phase 3 · completed

This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.

Next expected readout: February 2032 · NCT07152184 (registry estimate)

Reported efficacy

Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)

Result source: NCT00640601

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Quetiapine (Seroquel XR)
PANSS total, change—Not reported-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562
CGI-S, change—Not reported-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562
PANSS response—Not reported62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380
PSP, change—Not reported15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380
Relapse (% of patients)—Not reported—Not posted · NCT00159770

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel XR)
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel XR)
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562

PANSS response

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel XR)
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380

PSP, change

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel XR)
15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel XR)
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Quetiapine (Seroquel XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricQuetiapine (Seroquel XR)
Dropout rate
38%a
NCT00640601 · Phase 3
show 7 more results
16.5%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
20%
NCT00954122 · Phase 4 · registry result, not featured evidence
30.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
20.8%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
14.6%a
NCT00640601 · Phase 3
show 7 more results
7.3%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
4.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
2.6%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Serious AEs
11.2%a
NCT00640601 · Phase 3
show 7 more results
3.7%
NCT00640562 · Phase 3
0%Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
0%Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
0%
NCT00779506 · Phase 4 · registry result, not featured evidence
1.3%Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
—Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
somnolence 18%
dizziness 14.6%
sedation 14.2%
NCT00640601 · Phase 3
show 5 more results
somnolence 5.5%
dry months 4.6%
hypotension 4.6%
NCT00640562 · Phase 3
somnolence 3.2%
delusion 1.6%
dizziness 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
psychotic disorder 1.6%
sedation 1.6%
sleep disorder 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
constipation 25.5%
insomnia 23.4%
sedation 12.8%
NCT00779506 · Phase 4 · registry result, not featured evidence
somnolence 22.2% (placebo 5%)
weight increased 13.1% (placebo 3.7%)
dizziness 11.8% (placebo 0.6%)
NCT01810380 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Quetiapine (Seroquel XR)

Clinical Benefit 56.88% (n=295) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-CB 1.41 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
PANSS Total 10.95 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 2 more results
-33.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
-26.8 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Positive 2.36 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
-7.4 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Negative 3.67 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
-6.2 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
GAS 5.54 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-S 0.51 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 2 more results
-1.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
-1.46 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
CGI-I 0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
2.4 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
SOFAS 6.45 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CDSS 7.31 vs 5.53 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
HAM-D -29.83 vs -23.02 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
PANSS Total 102.26 vs 100.51 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
show 1 more result
-24 vs -15.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence

+ 22 further endpoints in the CSV export.

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Quetiapine (Seroquel XR)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.

Quetiapine (Seroquel XR): no structured comparison results are available for Bipolar Disorder.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Quetiapine (Seroquel XR)'s landscape